Beta Drugs Ltd

Beta Drugs Fund Raise

Beta Drugs Limited allotted 6,65,314 equity shares upon conversion of CCDs on May 25, 2026. This increases the company's paid-up share capital to ₹11.09 Crore.

Beta Drugs Fund Raise of ₹117 Cr

Beta Drugs Limited reported utilization of ₹117.01 Crore raised through preferential issues. The Monitoring Agency confirms funds were deployed for subsidiary upgradation and R&D.

Value

₹117.0 Cr

Beta Drugs Fund Raise of ₹4.86 Cr

Beta Drugs Limited has allotted 2,83,668 equity shares via a preferential issue at ₹1,712.49 per share, raising approximately ₹4.86 Crore. The shares were issued to 33 investors on a pari-passu basis, increasing the company's paid-up share capital to ₹10.42 Crore.

Value

₹4.86 Cr

Beta Drugs Fund Raise of ₹48.58 Cr

Beta Drugs Limited allotted 2,83,668 equity shares at ₹1712.49 each, totaling ₹48.58 Crore. This issuance is part of the consideration for the acquisition of Nivian Lifesciences Private Limited, expanding the company's equity base.

Value

₹48.58 Cr

Beta Drugs Fund Raise

Beta Drugs Limited provided a shareholding clarification regarding its proposed preferential issue. Following the issuance of equity shares and conversion of CCDs, the total share capital will increase to 1,10,85,872 shares, with promoter holding adjusting from 64.63% to 59.10%.